Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBT (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBT for 17 consecutive years, with -$8.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 77.3% to -$8.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$395.1 million, a 219.92% decrease, with the full-year FY2025 number at -$395.1 million, down 219.92% from a year prior.
  • EBT was -$8.9 million for Q4 2025 at Myriad Genetics, up from -$26.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $39.8 million in Q3 2021 to a low of -$330.6 million in Q2 2025.
  • A 5-year average of -$48.9 million and a median of -$34.8 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 191.08% in 2021, then plummeted 788.71% in 2025.
  • Myriad Genetics' EBT stood at -$43.5 million in 2021, then fell by 19.77% to -$52.1 million in 2022, then skyrocketed by 38.0% to -$32.3 million in 2023, then fell by 21.36% to -$39.2 million in 2024, then surged by 77.3% to -$8.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBT are -$8.9 million (Q4 2025), -$26.2 million (Q3 2025), and -$330.6 million (Q2 2025).